All articles by Vishnu Priyan
Vishnu Priyan
FDA grants approval for Gilead’s multi-drug resistant HIV-1 treatment
A long-acting HIV capsid inhibitor, Sunlenca is intended for dosing twice a year.
Lilly and ProQR to expand genetic medicine development agreement
Lilly will make an upfront payment and equity investment totalling $75m to ProQR under the latest agreement.
Merck and Kelun-Biotech enter ADC development deal
Kelun-Biotech is entitled to get payments of up to $9.3bn on meeting development, regulatory and sales milestones from Merck.
Moderna and UK government sign deal to establish mRNA facility
The centre is expected to offer access to a locally produced future mRNA vaccine portfolio against respiratory viruses.
EC approves Sobi-ADC’s Zynlonta for diffuse large B-cell lymphoma
With the approval, Zynlonta can be used in all member states of the European Union, Norway, Liechtenstein and Iceland.
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
US FDA grants approval for Radius’ Tymlos for osteoporosis in men
This approval is based on findings from the multicentre, double-blind, 12-month Phase III ATOM clinical trial.
Japan approves BMS’ Breyanzi for large B-cell lymphoma
The approval is based on trial findings in subjects with r/r aggressive B-cell non-Hodgkin lymphoma following first-line therapy.
Sanofi and Innate Pharma extend cancer therapeutics partnership
Innate is eligible to receive a total of up to $1.43bn in preclinical, clinical, regulatory and commercial milestone payments.
FDA grants approval for AbbVie’s major depressive disorder therapy
Cariprazine is a once-a-day oral atypical antipsychotic developed by AbbVie and Gedeon Richter.
EMA CHMP recommends Moderna’s Covid-19 booster for children
A Phase II/III trial of mRNA-1273.214 as a booster and initial regimen in children aged six months to five years is progressing.